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Background/Aims: Hereditary non-polyposis colorectal cancer or Lynch syndrome is an autosomal dominantly inherited disease 
with high penetrance, mostly due to mutations in the MLH1 and MSH2 genes. The aim of this study is to investigate the mutation 
spectrum of the MLH1 and MSH2 genes. Methodology: High risk colorectal cancer families were selected from overall 1053 consecu-
tive patients. Screening of germline mutations in the MLH1 and MSH2 was performed by direct sequencing and multiplex ligation-
dependent probe amplification. Results: Ten patients fulfilled the Amsterdam I/II criteria and Bethesda guidelines of the Lynch 
syndrome. Three novel mutations were identified in MLH1 and MSH2 genes, as well as two known mutations in the MLH1 gene. 
Large rearrangements in the MLH1 gene were found in two patients. Conclusions: The mutations in the MLH1 and MSH2 genes 
in Latvian high-risk families are highly heterogeneous. Combination of direct sequencing and MLPA is the most appropriate mo-
lecular method of detecting hereditary nonpolyposis colorectal cancer patients and family members at risk.
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Approximately ���% of colorectal cancer cases 
belong to t�e �ereditary nonpolyposis colorectal can-
cer �HNPCC� or Lync� syndrome. HNPCC is an auto-
somal dominantly in�erited disease wit� �ig� pene-
trance due to germline mutations in mismatc� repair 
genes. T�e increased overall mutation rate is associ-
ated wit� an elevated risk of developing early onset 
colorectal cancer as well as extracolonic tumors� suc� 
as endometrial and ovary cancer in women� stomac�� 
small bowel� pancreas� and ot�ers [�]. Overall sur-
vival is better in patients wit� HNPCC compared to pa-
tients wit� sporadic cancer [�]. About 7�% of HNPCC 
cases �ave developed due to t�e mutations distrib-
uted equally t�roug� t�e exons in t�e MLH1 and 
MSH2 genes [�� �]� and only some mutations �ave 
a proven founder effect [�]. HNPCC as a clinical syn-
drome is diagnosed according to t�e Amsterdam 
criteria and Bet�esda guidelines and allow t�e identi-
fication of �ig� risk families [�]. Family members wit� 
a confirmed mutation or at �ig� risk� if t�e mutation 
is unknown but diagnosis is clinically proven� s�ould 
take a screening colonoscopy every ��� years begin-
ning at age ����� [�]. Endometrial sampling and 
transvaginal ultrasonograp�y in women from HNPCC 
families is also considered to be useful starting at age 
����� [�� �]� as t�e risk of developing endometrial 
cancer for a woman in a HNPCC family is ���6�% [6]. 
Still� due to HNPCC most endometrial cancer cases 
are diagnosed symptomatically� not by transvaginal 
ultrasound or biopsy. Transvaginal ultrasound can 
be more �elpful in t�e case of ovarian cancer as t�e 
risk of developing it is about 6���% [6]. T�erefore� 
it is important to screen patients and t�eir relatives for 
mismatc� repair gene mutations in order to confirm 
t�e diagnosis of HNPCC and begin prevention mea-
sures for reducing t�e probability of developing cancer. 
T�is allows more accurate identification of patients 
from HNPCC families. In previous studies� it was con-
cluded t�at t�e use of t�e Amsterdam criteria for 
HNPCC patient diagnosis in Latvia is limited and muta-
tion spectrum differs from ot�er neig�boring countries 
[7� 8]. T�is study continues t�e researc� of mismatc� 
repair gene mutations in t�e case of HNPCC.
T�e aim of t�is study is to investigate t�e mutation 
spectrum of MLH1 and MSH2 in �ig� risk families and 
to accumulate information necessary for future diagnosis 
and consulting �ig� risk patients and t�eir family members.
PATIENTS AND METHODS
Patients wit� colorectal cancer corresponding 
to t�e Amsterdam criteria or Bet�esda guidelines were 
selected from ���� consecutive colorectal cancer pa-
tients at t�e Pauls Stradins Clinical University Hospital 
or counseled at t�e Hereditary Cancer cabinet during 
���������. Approval of Riga Stradins University �edi-
cal et�ics committee was obtained and all patients w�o 
participated in t�is study signed an informed consent 
form. Patients or t�eir relatives w�o participated in pre-
vious studies [7� �] were excluded. 
DNA was extracted from w�ole blood by t�e QIAgen 
FlexiGene DNA Kit. All DNA samples were subjected 
to w�ole sequencing of MLH1 and MSH2 as de-
scribed earlier [��� ��]. �utations were confirmed 
by sequencing bot� DNA strands on an independent 
PCR product. Samples wit� no mutation detected 
by sequencing were subjected to t�e multiplex 
ligation-dependent probe amplification ��LPA� 
analysis. �LPA and sequencing reactions were per-
formed using t�e SALSA �LPA P��� �LH�/�SH� kit 
��RC-Holland� t�e Net�erlands�. �LPA reactions 
were analyzed using t�e Applied Biosystems genetic 
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analyzer ABI����. T�e following databases were 
used for mutation analysis: INSIGHT-group database 
��ttp://www.insig�t-group.org/mutations/� and NCBI 
SNP database ��ttp://www.ncbi.nlm.ni�.gov/snp/�.
Table.  Patients and their families data  
(CRC — colorectal cancer, Ut — uterine cancer, Ov — ovarian cancer, Li — liver cancer, Pro — prostate cancer, CSU — cancer site unknown, d — died) 
Patient, 
age at CRC 
diagnosis
Pedigree
Diagno-
sis accor-
ding to
Gene status
D321, 41 y
I:1 I:2
Ut 46
CRC 66
d 66
Ut 48
CRC 65
CRC 43
d 43
CRC 32
d 34
CRC 37 CRC 41
II:5 II:3 II:4 II:1 II:2
III:2III:1
IV:1
III:3III:4 III:5 III:6
Amster-
dam cri-
teria I
MLH1 wt
MSH2 wt
J236, 58 y 
I:1 I:2
Ut 40
d 72
CRC 58
CRC 36
II:3 II:1 II:2
III:2III:1
Amster-
dam cri-
teria II
MLH1
1340delTGinsC
L447fsM490X
MSH2 wt
C321, 47 y
I:1 I:2
Ut 48
d 50
Ov 45
d 60
CSU 59
d 60
CSU 46
d 48
CRC 47
II:5 II:6 II:7II:3 II:4II:1 II:2
IV:1 IV:2
Amster-
dam cri-
teria II
MLH1 wt
MSH2 
288delGTinsA 
R96fsL173X
C450, 67 y
I:1 I:2
CRC 51
d 53
CRC 69
d 69
CRC 67
II:5II:3 II:4II:1 II:2
III:2III:1
IV:1
III:3 III:4III:5
Ov 65
d 65
Ut 48
d 50
Amster-
dam cri-
teria II
MLH1 wt
MSH2 wt
Patient, 
age at CRC 
diagnosis
Pedigree
Diagno-
sis accor-
ding to
Gene status
C152, 60 y
I:1 I:2
Li 82
d 84
Li 75
d 76
CRC 37
d 47
CRC 60
II:1 II:2
III:2III:1 III:3 III:4
Amster-
dam cri-
teria II
MLH1
1546C>T
Q516X
MSH2 wt
D500, 65 y
I:1 I:2
Ut 70
d 84
Ut 40
d 45
CRC 65
II:3 II:1 II:2
III:1
Amster-
dam cri-
teria II
MLH1 
6th exon dupli-
cation
MSH2 wt
A538, 50 y
I:1 I:2
CRC 73
d 73
Pro 65
d 65
CRC 50
II:3 II:4II:1II:2
III:1 III:2
Bethesda 
criteria
MLH1 12th exon 
deletion
MSH2 wt
E430, 43 y
I:1 I:2
CRC 45
d 60
CRC 43
II:3 II:1 II:2
III:1
Bethesda 
criteria
MLH1 
37G>T 
E13X
MSH2 wt
D583, 48 y
I:1 I:2
Ut 40
d 46
CRC 48
II:3 II:4 II:1 II:2
III:1
Bethesda 
criteria
MLH1 1959G>T
MSH2 wt
E595, 60 y
I:1 I:2
CRC 46
d 47
CRC 60
II:1
Bethesda 
criteria
MLH1 wt
MSH2 wt
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RESULTS
Amsterdam I criteria define HNPCC families ac-
cording to family colorectal cancer �istory and t�e 
age of onset; at least two successive generations and 
t�ree patients s�ould be involved� at least one of w�ic� 
is a first degree relative to t�e ot�er two� one of t�e 
cancers s�ould be diagnosed before age �� and fam-
ily adenomatous polyposis �FAP� s�ould be excluded. 
Amsterdam II criteria also include cancers t�at are as-
sociated wit� t�e HNPCC� suc� as endometrial� small 
intestine� stomac�� and ot�ers. Bet�esda guidelines 
are used to test colorectal cancers for microsatellite in-
stability� and it is proven� t�at t�ese are more applicable 
for detecting patients w�o s�ould undergo genetic 
testing [�]. In t�is study� t�e main criteria used from 
t�e Bet�esda guidelines were t�e young age of onset 
�before ��� in one of t�e affected family members.
Ten index patients were identified from ���� con-
secutive colorectal cancer patients in Latvia by fam-
ily �istory according to t�e Amsterdam I/II criteria 
or Bet�esda guidelines. Among t�em � patient fulfilled 
t�e Amsterdam I criteria ��.�%�� � fulfilled t�e Amster-
dam II criteria ��.�7%� and � fulfilled t�e Bet�esda 
guidelines ��.�8%�. �edical and family �istories are 
summarized in t�e Table. 
Seven patients out of �� were found to �arbor 
mutations in t�e MLH1 or MSH2 genes including large 
rearrangements. Four out of � patients meeting t�e 
Amsterdam II criteria were �arboring mutations. T�ree 
out of � patients meeting t�e Bet�esda guidelines were 
�arboring mutations.  No mutation was detected in t�e 
only patient meeting t�e Amsterdam I criteria.
DNA sequencing revealed MLH1 and MSH2 muta-
tions in five index patients. Four of t�ose mutations 
including two nonsense mutations �MLH1, �7G>T and 
���6C>T� and two frames�ift mutations �MLH1� 
����delTGinsC and MSH2� �88delGTinsA� are clinical-
ly significant� as t�ey result in a truncated protein. One 
nonsense mutation in t�e first exon of t�e MLH1 gene 
�7G>T �E��X� was discovered in patient E���. Patient 
C��� carried t�e nonsense mutation ���6C>T �Q��6X� 
in t�e MLH1 exon �6. Patient C��� �ad a mutation in t�e 
MSH2 exon � �88delGTinsA w�ic� leads to a prema-
ture stop codon at t�e amino acid position �7�. �uta-
tion in t�e MLH1 exon �� ����delTGinsC� discovered 
in patient J��6� truncates protein� leading to premature 
stop at codon ���. Patient J��6’s family members 
were available for analysis: �is son was diagnosed wit� 
colorectal cancer at age �6� and daug�ter ��� years 
old at present� is not diagnosed wit� any cancer. Bot� 
siblings carry t�e ����delTGinsC mutation in t�e 
MLH1 gene. In patient D�8�� t�e MLH1 gene mutation 
���� G>T was found in exon �7. 
�LPA analysis revealed two large rearrangements. 
In patients A��8 and D���� large rearrangements 
of t�e MLH1 gene were found using �LPA. Patient 
A��8 �ad t�e deletion of exon ��. Patient D��� �as 
t�e duplication of exon 6.
None of all t�e mutations t�at were found in t�is 
study coincided wit� t�e previously reported mutations 
in Latvia [7� �].
DISCUSSION
About ���� new colorectal cancer cases are 
diagnosed in Latvia every year and approximately 
��� of t�em at t�e Pauls Stradins Clinical University 
Hospital. Less t�an �% are FAP cases [��]. As con-
cluded before� t�e HNPCC rate from consecutive 
colorectal cancer patients in Latvia is about �% [7] 
and about �� primary diagnosed HNPCC patients 
can be expected in Latvia per year. T�e HNPCC is es-
timated at about �.��% wit�in t�e population of Latvia 
[��]. In ot�er studies� �ereditary colorectal cancer 
is estimated at ���% from all t�e colorectal cancer 
cases [��� ��] and �.��% from t�e total population 
[�6]. It is possible t�at t�e number of HNPCC cases 
in Latvia is underestimated due to a lower reliability 
of patients’ family data or t�e lack of full informa-
tion about t�e medical �istory of a family. It �as been 
described t�at finding �ereditary cancer families 
in Latvia is a common problem because of small fami-
lies� as t�ere is small number of first degree relatives 
and not all patients cooperate wit� t�e doctors [�7]. 
Families wit� �ereditary cancer syndrome are more 
easily detected if t�e family is large. Previously in Latvia 
a statistically significant difference was observed be-
tween t�e size of t�e family diagnosed wit� �ereditary 
cancer� according to defined criteria� and families wit� 
non-diagnostic findings. T�e mean numbers of blood 
relatives wit�in t�e families wit� �ereditary cancer 
syndromes were ��.6 and ��.�� w�ile t�e mean number 
of blood relatives for t�e families not diagnosed wit� 
�ereditary cancer syndrome was �.� [�7]. As proven 
by case of �ereditary breast cancer families in Latvia 
during population screening� t�e results of clinical 
screening and mutation screening do not overlap and 
molecular screening reveals more mutation carriers 
as clinical criteria [�7]. Similar results were observed 
in t�e case of HNPCC from patients corresponding 
wit� t�e Amsterdam criteria — mutations were found 
in some of t�e patients� and mutation screening in con-
secutive patients revealed patients wit�out familial 
cancer �istory [�8]. In t�is study� only one patient 
is diagnosed according to t�e Amsterdam I criteria 
and t�e patient did not �arbor any mutation in t�e 
MLH1 and MSH2 genes. Five patients were diagnosed 
according to t�e Amsterdam II criteria� w�ic� also in-
cluded cancers t�at were associated wit� t�e HNPCC 
syndrome� not only colorectal cancer. Out of t�ose 
five patients� four of t�em �ad mismatc� repair gene 
mutations. From four patients w�o corresponded wit� 
t�e Bet�esda guidelines� t�ree patients �ad germline 
mutations in mismatc� repair genes. T�ree families did 
not �ave any mutation in t�e MLH1 and MSH2 genes. 
T�e syndrome of t�ose patients could be due to t�e 
mutations in ot�er mismatc� repair genes or associ-
ated wit� an unknown susceptibility locus or epimuta-
tions [�����]. Up until now� several MLH1� MSH2 and 
�� Experimental Oncology ��� ������ ���� ��arc��
MSH6 gene mutations in t�e case of HNPCC �ave 
been found in Latvia [7� �]� but none of t�ese mutations 
were found in our researc�. None of t�e mutations �ad 
a proven founder effect in Latvian colorectal cancer 
patients� alt�oug� t�e mutation MLH1 ����+� A>G t�at 
was found in Latvia [7] is described in Polis� and Finn-
is� populations [8� ��]. 
Information about t�e MLH1 ����G>T mutation 
is not consequential and t�ere is a possibility t�at t�e 
exact mutation does not affect mismatc� repair. T�e 
mutation is predicted to form alternative splice site� 
resulting in exon skipping [��]� alt�oug� information 
available in t�e INSIGHT-group database does not 
conclude pat�ogenesis of t�is mutation in all cases. 
However� t�is mutation can be considered a rare poly-
morp�ism� as t�ere is no p�enotypic consequence 
[�8� ��]. We concluded t�at 6 mutations out of 7 were 
pat�ogenic� as t�ey resulted in altered protein� t�us 
affecting mismatc� repair and resulting in t�e devel-
opment of cancer. T�e mutation MLH1 �7G>T �E��X� 
�as been reported in t�e INSIGHT-group database.
�utations in t�e MLH1 and MSH2 genes are �ig�ly 
�eterogeneous in Latvia. Combination of direct se-
quencing of t�e MLH1 and MSH2 genes and �LPA 
is t�e most appropriate molecular met�od of detecting 
HNPCC patients and family members at risk.
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